619 related articles for article (PubMed ID: 29415351)
1. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma.
Quach H; Benson S; Haysom H; Wilkes AM; Zacher N; Cole-Sinclair M; Miles Prince H; Mollee P; Spencer A; Joy Ho P; Harrison SJ; Lee C; Augustson B; Daly J
Intern Med J; 2018 Feb; 48(2):210-220. PubMed ID: 29415351
[TBL] [Abstract][Full Text] [Related]
2. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma.
Chari A; Arinsburg S; Jagannath S; Satta T; Treadwell I; Catamero D; Morgan G; Feng H; Uhlar C; Khan I; Doshi P; Usmani S
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):44-51. PubMed ID: 29054515
[TBL] [Abstract][Full Text] [Related]
3. Daratumumab: Therapeutic asset, biological trap!
Deneys V; Thiry C; Frelik A; Debry C; Martin B; Doyen C
Transfus Clin Biol; 2018 Feb; 25(1):2-7. PubMed ID: 29336950
[TBL] [Abstract][Full Text] [Related]
4. Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies.
Lancman G; Arinsburg S; Jhang J; Cho HJ; Jagannath S; Madduri D; Parekh S; Richter J; Chari A
Front Immunol; 2018; 9():2616. PubMed ID: 30498492
[TBL] [Abstract][Full Text] [Related]
5. Impact of new myeloma agents on the transfusion laboratory.
Jones AD; Moayeri M; Nambiar A
Pathology; 2021 Apr; 53(3):427-437. PubMed ID: 33707006
[TBL] [Abstract][Full Text] [Related]
6. New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing.
De Vooght KM; Oostendorp M; van Solinge WW
Curr Opin Hematol; 2016 Nov; 23(6):557-562. PubMed ID: 27389485
[TBL] [Abstract][Full Text] [Related]
7. Daratumumab: A review of current indications and future directions.
Hill E; Morrison C; Kazandjian D
Semin Oncol; 2022 Feb; 49(1):48-59. PubMed ID: 35184871
[TBL] [Abstract][Full Text] [Related]
8. Alloimmunisation rate of patients on Daratumumab: A retrospective cohort study of patients in England.
Bullock T; Foster A; Clinkard B
Transfus Med; 2021 Dec; 31(6):474-480. PubMed ID: 34405478
[TBL] [Abstract][Full Text] [Related]
9. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
[TBL] [Abstract][Full Text] [Related]
10. High-Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action.
Adams HC; Stevenaert F; Krejcik J; Van der Borght K; Smets T; Bald J; Abraham Y; Ceulemans H; Chiu C; Vanhoof G; Usmani SZ; Plesner T; Lonial S; Nijhof I; Lokhorst HM; Mutis T; van de Donk NWCJ; Sasser AK; Casneuf T
Cytometry A; 2019 Mar; 95(3):279-289. PubMed ID: 30536810
[TBL] [Abstract][Full Text] [Related]
11. Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy.
Anani WQ; Marchan MG; Bensing KM; Schanen M; Piefer C; Gottschall JL; Denomme GA
Transfusion; 2017 Jun; 57(6):1470-1479. PubMed ID: 28150308
[TBL] [Abstract][Full Text] [Related]
12. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy.
Oostendorp M; Lammerts van Bueren JJ; Doshi P; Khan I; Ahmadi T; Parren PW; van Solinge WW; De Vooght KM
Transfusion; 2015 Jun; 55(6 Pt 2):1555-62. PubMed ID: 25988285
[TBL] [Abstract][Full Text] [Related]
13. Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
Plesner T; van de Donk N; Richardson PG
Cells; 2020 Feb; 9(2):. PubMed ID: 32041300
[TBL] [Abstract][Full Text] [Related]
14. Role of Anti-CD38 Monoclonal Antibodies in the Treatment of Adult Immune Hematological Diseases.
Yang EH; Muhsen IN; Samarkandi H; El Fakih R; Aljurf M; Hanbali A
Hematol Oncol Stem Cell Ther; 2023 Jul; 17(1):4-12. PubMed ID: 37581463
[TBL] [Abstract][Full Text] [Related]
15. The Challenges of Daratumumab in Transfusion Medicine.
Dizon MF
Lab Med; 2017 Feb; 48(1):6-9. PubMed ID: 27794527
[TBL] [Abstract][Full Text] [Related]
16. Optimizing transfusion management of multiple myeloma patients receiving daratumumab-based regimens.
Phou S; Costello C; Kopko PM; Allen ES
Transfusion; 2021 Jul; 61(7):2054-2063. PubMed ID: 33960433
[TBL] [Abstract][Full Text] [Related]
17. Review: Effects of anti-CD38 monoclonal antibodies on red blood cell transfusion and interventions.
Song J; Fu R
J Clin Lab Anal; 2021 Dec; 35(12):e23832. PubMed ID: 34752645
[TBL] [Abstract][Full Text] [Related]
18. Transfusion management in multiple myeloma patients receiving daratumumab: Experience of a single tertiary care centre.
Solves P; Tur S; Arnao M; Freiria C; Dominguez L; Pons MJ; Gómez I; Sanz GF; Carpio N
Transfus Apher Sci; 2020 Apr; 59(2):102658. PubMed ID: 31607551
[No Abstract] [Full Text] [Related]
19. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.
Moreau P; van de Donk NW; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos MV
Drugs; 2016 May; 76(8):853-67. PubMed ID: 27113582
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab for the treatment of multiple myeloma.
Touzeau C; Moreau P
Expert Opin Biol Ther; 2017 Jul; 17(7):887-893. PubMed ID: 28434255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
